Biotech companies at ObesityWeek 2026
Nov 14–17, 2026 National Harbor, MD ~4.4k attendees Website
67 biotech companies are at ObesityWeek 2026 — 87 presentations on the program and 10 with a booth in the exhibit hall. Most represented: Wave Life Sciences (4 on the program), Deep Apple Therapeutics (4 on the program), ProLynx (3 on the program). 21 of them have their own page in this guide. As of Nov 12, 2026.
Topic
Top represented
Showing 1–11 of 67 organizations
| Organization | ObesityWeek 2026 Attendance |
|---|---|
Wave Life Sciences Cambridge, MA | ◇Bronze Sponsor |
RNA medicines company whose pipeline includes WVE-007 for obesity, plus programs in alpha-1 antitrypsin deficiency and PNPLA3-linked liver disease. | Booth Exhibiting at Booth 428 Sat, Nov 147pm–9:30pmSun, Nov 159:30am–4pmMon, Nov 169:30am–4pm Talk Sat Nov 14 11:45am–1:15pm Rethinking Success in the Treatment of Overweight and Obesity Through Body Composition: What Are We Made of? Asks whether body composition, not weight loss alone, should measure obesity treatment success, and reviews activin E biology and small interfering RNA drugs. Interventional and clinical studiesPopulation health and epidemiologyClinical obesity care and professional practiceMetabolism and integrative physiologyObesity pharmacotherapy and drug development Talk Sat Nov 14 11:55am–12:10pm Changing the Treatment Paradigm in Overweight and Obesity Management Interventional and clinical studiesPopulation health and epidemiologyClinical obesity care and professional practiceMetabolism and integrative physiologyObesity pharmacotherapy and drug development Talk Sat Nov 14 12:10pm–12:35pm Beyond The Scale: The Clinical Relevance of Body Composition, Body Fat Distribution and Lean Mass Interventional and clinical studiesPopulation health and epidemiologyClinical obesity care and professional practiceMetabolism and integrative physiologyObesity pharmacotherapy and drug development Talk Sat Nov 14 12:35pm–1:00pm From Genetic Evidence to Therapeutic Hypothesis: the INHBE-Activin E Pathway as a Target for Obesity Management Interventional and clinical studiesPopulation health and epidemiologyClinical obesity care and professional practiceMetabolism and integrative physiologyObesity pharmacotherapy and drug development Talk Sat Nov 14 1:10pm–1:15pm Rethinking Success: Where Should Obesity Treatment Go? Interventional and clinical studiesPopulation health and epidemiologyClinical obesity care and professional practiceMetabolism and integrative physiologyObesity pharmacotherapy and drug development Talk Sat Nov 14 4:30pm–4:45pm Poster Sun Nov 15 2:30pm–3:30pm Interim Data From INLIGHT: A Phase 1 Study of WVE-007 in Adults Living With Overweight and Obesity Obesity pharmacotherapy and drug developmentInterventional and clinical studies |
Drug discovery company using cryo-EM and AI to find oral small molecules for obesity targets such as MC4R, GIPR and amylin receptors. | Poster Sat Nov 14 7:30pm–8:30pm Discovery of DAT-9232: A Highly Selective Dual MC4R/MC3R Agonist with Balanced Signaling Profiles Metabolism and integrative physiology Poster Sun Nov 15 2:30pm–3:30pm Integrating High-Throughput Cryo-EM and AI Foundation Models for Amylin Receptor Drug Discovery Obesity pharmacotherapy and drug developmentInterventional and clinical studies Poster Sun Nov 15 2:30pm–3:30pm Discovery of DAT-004, an Oral Small-Molecule GIP Receptor Antagonist for the Treatment of Obesity Obesity pharmacotherapy and drug developmentInterventional and clinical studies Poster Mon Nov 16 2:30pm–3:30pm Structure-Based Discovery of Novel Orthosteric and Allosteric GIP-R Agonists for Metabolic Therapy Chronic disease and obesity complications |
P ProLynx San Francisco, CA | |
Biotech using a linker platform to make ultralong-acting anti-obesity peptide therapeutics. | Poster Sat Nov 14 7:30pm–8:30pm Unlipidated Anti-Obesity Peptides Achieve Body Weight Reductions Similar to Those of Lipidated Counterparts Neuroscience of appetite and eatingObesity pharmacotherapy and drug development Poster Sat Nov 14 7:30pm–8:30pm Ultralong-Acting Amylin Agonist Elicits Sustained 12-Week Weight Loss in DIO Rats After Single Dose Obesity pharmacotherapy and drug developmentMetabolism and integrative physiology Poster Sat Nov 14 7:30pm–8:30pm A Platform for Ultralong-Acting Anti-Obesity Peptide Therapeutics Independent of Lipidation Neuroscience of appetite and eatingObesity pharmacotherapy and drug development |
RP Rivus Pharmaceuticals Charlottesville, VA | |
Develops obesity and metabolic drugs aimed at fat loss while preserving muscle, including a preclinical GLP-1 receptor agonist. | Poster Sat Nov 14 7:30pm–8:30pm RV-8451, a Pre-Clinical, Muscle-Preserving GLP-1R NPA, Outperforms Orforglipron in Obesity Models Obesity pharmacotherapy and drug developmentMetabolism and integrative physiology Poster Sun Nov 15 2:30pm–3:30pm Rescuing Lean Mass: GLP-1R NPA RV-8451 Reverses Orforglipron-Induced Muscle Loss in DIO Mouse Model Interventional and clinical studies Poster Sun Nov 15 2:30pm–3:30pm Beyond Caloric Restriction: RV-8451 GLP-1R NPA Drives Fat-Specific Weight Loss in a DIO Mouse Model Interventional and clinical studies |
◇Bronze Sponsor | |
Clinical-stage biotech building a portfolio of obesity medicines meant to give patients options at each stage of treatment. | Booth Exhibiting at Booth Suite 17 Sat, Nov 147pm–9:30pmSun, Nov 159:30am–4pmMon, Nov 169:30am–4pm Poster Mon Nov 16 2:30pm–3:30pm Natural History & Real-World Effectiveness of Obesity Management Medications: REFLECT Design/Methods Population health and epidemiology Poster Mon Nov 16 2:30pm–3:30pm Quantifying the Clinical Unmet Need in Adults With Class II and III Obesity in the United States Population health and epidemiologyNutrition, diet and food |
Drug developer working on oral small-molecule GLP-1 and GIP receptor agonists for obesity. | Poster Sun Nov 15 2:30pm–3:30pm Discovery of AMB-895, a Long-Acting and Novel, Oral Small Molecule GLP-1 Receptor Agonist Obesity pharmacotherapy and drug developmentInterventional and clinical studies Poster Sun Nov 15 2:30pm–3:30pm Discovery and Nonclinical Profile of AMB-131, a Novel, Oral Small Molecule GIP Receptor Antagonist Obesity pharmacotherapy and drug developmentInterventional and clinical studies |
Biotech developing NAMPT activators, with obesity and metabolic disease among its programs. | Poster Sat Nov 14 7:30pm–8:30pm Pharmacologic NAMPT Activation Improves Metabolism with Weight-Lowering Effects in DIO Mice Metabolism and integrative physiology Poster Sat Nov 14 7:30pm–8:30pm Weight-of-Evidence Carcinogenicity Risk Assessment of the NAMPT Activator SIR4156 in Obesity Obesity pharmacotherapy and drug developmentMetabolism and integrative physiology |
Developer of antibody-peptide conjugates, working on anti-myostatin and anti-GIPR candidates for obesity. | Poster Sat Nov 14 7:30pm–8:30pm STAR-306: An Anti-Myostatin-Incretin APC Improves Lean Mass Retention in a Preclinical DIO Model Obesity pharmacotherapy and drug developmentMetabolism and integrative physiology Poster Sat Nov 14 7:30pm–8:30pm Preclinical Characterization of a First-in-Class Anti-GIPR-GLP1/Amylin Antibody Peptide Conjugate Obesity pharmacotherapy and drug developmentMetabolism and integrative physiology |
SB Syntis Bio Boston, MA | |
Develops a once-daily oral pill that temporarily coats the upper small intestine to mimic the metabolic effects of gastric bypass. | Poster Mon Nov 16 2:30pm–3:30pm Single Ascending Dose Study to Evaluate the Safety, Tolerability, PK, and PD of SYNT-101 in Adults Pediatric and adolescent obesityObesity pharmacotherapy and drug development Poster Mon Nov 16 2:30pm–3:30pm 28-Day Study to Evaluate the Safety, Tolerability, PK, and PD of SYNT-101 in Adults with Obesity Pediatric and adolescent obesityObesity pharmacotherapy and drug development |
Amylyx Pharmaceuticals Cambridge, MA | ◇Bronze Sponsor |
Develops investigational therapies for endocrine and neurodegenerative conditions, including treatment for hypoglycemia after bariatric surgery. | Booth Exhibiting at Booth 701, Suite 1 Sat, Nov 147pm–9:30pmSun, Nov 159:30am–4pmMon, Nov 169:30am–4pm Session Sun Nov 15 5:30pm–8:00pm Session Mon Nov 16 7:30am–8:30am Poster Mon Nov 16 2:30pm–3:30pm Identification of Individuals With Post-Bariatric Hypoglycemia in US Claims Data: Insights and Opportunities Population health and epidemiology |
Rhythm Pharmaceuticals Boston, MA | ◆Silver Sponsor |
Biopharmaceutical company developing precision medicines for rare neuroendocrine diseases, including acquired hypothalamic obesity. | Booth Exhibiting at Booth 401 Sat, Nov 147pm–9:30pmSun, Nov 159:30am–4pmMon, Nov 169:30am–4pm Talk Sun Nov 15 12:00pm–1:00pm Defining Acquired Hypothalamic Obesity: An International Expert Consensus on Diagnostic Criteria in Children and Adults Unveils 2026 international consensus criteria for diagnosing acquired hypothalamic obesity, a rare form caused by hypothalamic damage, in children and adults. Policy and public health Talk Mon Nov 16 7:30am–8:30am The Obesity Diagnosis You May Be Missing: Acquired Hypothalamic Obesity Case-based guide to spotting obesity caused by hypothalamic damage from tumors, brain injury or stroke, with Phase 3 results for a targeted drug. Clinical obesity care and professional practicePediatric and adolescent obesityObesity pharmacotherapy and drug developmentNeuroscience of appetite and eatingInterventional and clinical studies |
Find buyers from biotech companies
Tell us what you sell and we’ll find the people at these biotech companies most likely to buy it.
- Who to contact
- Their contact info
- What to say
- Free, no sign-up
Browse ObesityWeek 2026 by
Organization type
Topic
- Obesity pharmacotherapy and drug development 251
- Clinical obesity care and professional practice 196
- Interventional and clinical studies 231
- Metabolism and integrative physiology 217
- Nutrition, diet and food 164
- Pediatric and adolescent obesity 117
- Population health and epidemiology 156
- Chronic disease and obesity complications 224
- Neuroscience of appetite and eating 97
- Bariatric surgery and devices 58
- Policy and public health 102
Exhibit hall
Everyone
Not affiliated with or endorsed by The Obesity Society (TOS), ObesityWeek® or the American Society for Metabolic and Bariatric Surgery (ASMBS). Submit a correction